Good morning :)
$
₹
Evogene

Evogene

EVGN

NASDAQ
Asset Logo

Evogene

EVGN

NASDAQ
$0.492.28% (-0.01)
$
₹
$0.492.28% (-0.01)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $8.5M the stock is ranked 5774

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

6.17
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-1.75
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 2 analysts' reports

Buy
2 analysts
Hold
0 analyst
Sell
0 analyst

Analysts expect a +323.56% price upside over the next year

Current Price$0.49
Target Price$2.15

Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD); and with ELEO, Inc. to develop oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases. The company was incorporated in 1999 and is headquartered in Rehovot, Israel.
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD); and with ELEO, Inc. to develop oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases. The company was incorporated in 1999 and is headquartered in Rehovot, Israel.

Peers

Peers

AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
72.44
72.44
1Y Return
19.08%
19.08%
Buy Reco %
57.14
57.14
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
27.17
27.17
1Y Return
41.43%
41.43%
Buy Reco %
46.87
46.87
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
27.55%
27.55%
Buy Reco %
63.33
63.33
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
31.84
31.84
1Y Return
31.43%
31.43%
Buy Reco %
52.94
52.94
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
20.49
20.49
1Y Return
45.3%
45.3%
Buy Reco %
76.00
76.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Evogene -6.170
AbbVie Inc72.4450.450.37
Amgen Inc27.1720.542.13

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

0.3
3.8
0.3
-5.3
0.3
-5.8
0.3
-1.7
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue4.190.601.741.612.440.880.310.310.330.34
Net Income-3.86-5.41-7.630.42-2.58-4.463.87-5.30-5.87-1.76
Net Profit Margin-92.19%-895.70%-438.50%26.50%-105.85%-504.75%1241.66%-1690.76%-1757.48%-509.51%
See CostsAll values in $ Million

Frequently asked questions

Frequently asked questions

  1. Evogene (EVGN) share price today is $0.49 as of September 10, 2026 at 1:30 AM IST. The stock touched a day high of $0.52 and a day low of $0.49.

  2. Evogene stock trades on NASDAQ under the ticker symbol EVGN.

  3. Evogene's market capitalization is $8.49M as of September 10, 2026 at 1:30 AM IST.

  4. Evogene's price-to-earnings (P/E) ratio is N/A as of September 9, 2026.

  5. Evogene's price-to-book (P/B) ratio is 6.17 as of September 9, 2026.

  6. Yes, You can buy Evogene shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Evogene shares in three steps: 1. Search Evogene on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Evogene trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Evogene (EVGN) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 20.1612 shares at the current price of $0.49.

Loading...